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Vascular access dysfunction contributes to patient morbidity
during maintenance hemodialysis. In this study we
determined if knockout of heme oxygenase-1 predisposed to
malfunction of arteriovenous fistulas. After three weeks, all
fistulas in wild type mice were patent whereas a third of the
fistulas in knockout mice were occluded and these exhibited
increased neointimal hyperplasia and venous wall thickening.
Heme oxygenase-1 mRNA and protein were robustly induced
in the fistulas of the wild type mice. In the knockout mice
there was increased PAI-1 and MCP-1 expression, marked
induction of MMP-2 and MMP-9, but similar expression of
PDGFa, IGF-1, TGF-b1, VEGF, and osteopontin compared to
wild type mice. We conclude that heme oxygenase-1
deficiency promotes vasculopathic gene expression,
accelerates neointimal hyperplasia and impairs the
function of arteriovenous fistulas.
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Vascular access dysfunction represents the single most
important determinant of morbidity and mortality in
patients on maintenance hemodialysis.1–11 Of the available
vascular accesses, the arteriovenous fistula (AVF) is the
favored modality, and yet these accesses commonly fail to
subserve the desired function:1–11 AVFs may never attain
maturation and thereby never fully acquire the capacity to
accommodate and sustain the heightened rate of blood flow
required for effective dialysis; additionally, after variable
periods of adequate function, blood flow may be increasingly
impeded as the patency of the AVF is lost due to venous
stenosis and thrombosis. Venous stenosis of the AVF results
from neointimal hyperplasia, the latter representing an
expansive lesion consisting of proliferating and migrating
cells, and matrix accumulation. Neointimal hyperplasia is not
only instrumental in the late failure of the AVF, but such
lesions, when they occur at juxta-anastomotic sites in the
AVF, commonly account for maturational failure of AVFs.
The failure of hemodialysis arteriovenous grafts is also largely
accounted for by neointimal hyperplasia.12 Understanding
the pathogenesis of neointimal hyperplasia is thus a
fundamental issue in elucidating the basis for vascular access
dysfunction.1–12
This study was prompted by two seminal studies
published in this journal in 2006.13,14 The first study, that
by Lin et al.,13 demonstrated that impaired patency and
functional failure of AVFs were more likely to occur in
patients with HO-1 (heme oxygenase-1) gene polymorph-
isms characterized by relatively long GT repeats; these novel
findings suggest that expression of HO-1 may influence the
viability of AVFs. HO-1, the inducible HO isoform, can
confer protective effects against diverse insults, including
those affecting the kidney and vasculature, and involving
actions that may be anti-inflammatory, antioxidant, or
antiproliferative in nature.15–21
The second study upon which the present observations are
based is that by Castier et al.,14 which introduced and
characterized a novel murine AVF model; this model
recapitulates the salient features of dysfunctional AVFs in
humans, in particular, prominent neointimal hyperplasia.
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Using this model in HO-1/ mice, this study examined
the functional significance of HO-1 as a determinant of the
functionality and form of an AVF.
RESULTS
After 3 weeks, the AVFs in all 16 HO-1þ /þ mice were fully
patent, whereas no flow occurred in 5 of the 15 AVFs in
HO-1/ mice; patency rates for the AVF were thus reduced
from 100% in HO-1þ /þ mice to 67% in HO-1/ mice
(Po0. 05, Fischer’s exact test). This impaired patency was
attended by more exuberant venous neointimal hyperplasia
(Figures 1 and 2). Morphometric studies of the AVF in
HO-1/ mice demonstrated increased thickness of
the venous wall and decreased luminal area/venous wall
cross-sectional area (Figure 2).
Expression of genes relevant to vascular injury and
vascular access dysfunction was assessed 1 week after
anastomosis. HO-1 was markedly induced in the AVF in
HO-1þ /þ mice, whereas no expression of HO-1 was
observed in HO-1/ mice (Figure 3). Expression of the
proinflammatory, procoagulant gene, plasminogen activator
inhibitor-1 (PAI-1), was markedly increased in the AVF in
HO-1/ mice as compared with the AVF in HO-1þ /þ mice;
expression of MCP-1 mRNA was increased in HO-1/ mice
as compared with HO-1þ /þ mice both in the vein of the
AVF and in the contralateral (intact) vein. Platelet-derived
growth factor-a (PDGFa) was increased to a comparable
degree in the AVF in HO-1þ /þ and HO-1/ mice. The
pattern observed for PDGFa was broadly seen for a number
of growth factors/cytokines, including transforming growth
factor-b1, insulin-like growth factor-1 (IGF-1), and osteo-
pontin; vascular endothelial growth factor mRNA expression
in the AVF in HO-1þ /þ and HO-1/ mice was also
comparable, and not increased above the contralateral side
(data not shown). Strong HO-1 protein expression in the
AVF in HO-1þ /þ mice was exhibited predominantly by cells
with phenotypic characteristics of smooth-muscle cells
(Figure 3e and f).
As interest is focused on metalloproteinases in vascular
injury and access dysfunction,5,6,8,22–24 we assessed two
relevant metalloproteinases. Matrix metalloproteinase-9
(MMP-9) mRNA was dramatically increased in the AVF in
HO-1/ mice as compared to HO-1þ /þ mice, and was
attended by increased enzyme activity and protein expression
(Figure 4). Increased activity and protein expression were
also observed for MMP-2 (data not shown).
DISCUSSION
That certain polymorphisms in the HO-1 gene increase
the risk for dysfunction of human AVFs suggests that HO-1
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Figure 1 | Representative histological sections of the vein
of the AVF in HO-1þ /þ and HO-1/ mice at the level of the
anastomosis examined 3 weeks after creation of the AVF.
(a) Low-power view of the vein of the AVF in HO-1þ /þ mice
(original magnification  50). (b) Low-power view of the vein
of the AVF in HO-1/ mice (original magnification  50).
(c) High-power view of the vein of the AVF in HO-1þ /þ mice
(original magnification  100). (d) High-power view of the vein
of the AVF in HO-1/ mice (original magnification  100).
Venous neointimal hyperplasia (marked by arrows) in the AVF was
markedly increased in HO-1/ mice. Foci of calcification were
observed in the AVF in HO-1þ /þ and HO-1/ mice, and were
more prominent in the latter group (data not shown). The
histological appearance of the contralateral, intact (control)
jugular vein in HO-1þ /þ and HO-1/ mice was normal (data not
shown). All sections are stained by hematoxylin and eosin.
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Figure 2 | Morphometric analyses of the vein in the AVF in
HO-1þ /þ and HO-1/ mice undertaken 3 weeks after
creation of the AVF. (a) Venous wall thickness. In each jugular
vein, thickness of the venous wall was measured at 12 sagittal
sections evenly spaced around the circumference of the venous
wall of the AVF at the level of the anastomosis, and the mean
value for each vein was determined; n¼ 8 and n¼ 9 for the vein in
the AVF in HO-1þ /þ and HO-1/ mice, respectively; n¼ 4 for the
control vein in HO-1þ /þ and HO-1/ mice. (b) Luminal area/
venous wall cross-sectional area. In sections of the vein at the
level of the anastomosis, the circumferential profiles of the lumen
and the external elastic lamina of the venous wall were
delineated, the areas encompassed by these boundaries were
determined, and the ratio of the luminal area to the venous wall
cross-sectional area was calculated; n¼ 8 and n¼ 9 for the vein in
the AVF in HO-1þ /þ and HO-1/ mice, respectively; n¼ 4 for the
control vein in HO-1þ /þ and HO-1/ mice. *Po0.05, HO-1/
mice versus HO-1þ /þ mice for that index for the vein in the AVF;
wPo0.05, HO-1/ mice versus HO-1þ /þ mice for that index for
the control vein. The control was provided by the contralateral,
intact, jugular vein.
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expression may influence the viability of human AVFs.13
However, as analyses of these HO-1 gene polymorphisms
were not accompanied by assessment of HO-1 expression or
HO activity,13 it is uncertain whether decreased or increased
HO-1 expression/HO activity confers an increased risk for
AVF dysfunction observed with these polymorphisms. In
other diseases, lesser inducibility of HO-1 may be associated
with HO-1 polymorphisms characterized by long GT
repeats,25–27 thus raising the possibility that diminished
HO-1 expression/HO activity may contribute to the
increased risk for AVF dysfunction as observed by Lin et al.
To the best of our knowledge, our findings are the first to
demonstrate that the failure to express HO-1 adversely affects
an AVF in a murine model.
Accentuated neointimal hyperplasia occurred in the AVF
of HO-1/ mice, and in one-third of these, blood flow
ceased; characterizing the cellular composition of the AVF in
HO-1/ mice is the focus of future studies. Such
accentuated neointimal hyperplasia may reflect enhanced
expression of PAI-1 and MCP-1, both of which are
inhibitable by HO-1 and its products;28–31 additionally, the
heightened PAI-1 expression in the AVF of HO-1/ mice
may exert thrombotic effects, the latter likely contributing to
AVF failure in these mice. The AVF in HO-1þ /þ and HO-1/
mice exhibited comparable mRNA expression for assorted
cytokines – PDGFa, IGF-1, transforming growth factor-b1,
osteopontin – incriminated in neointimal hyperplasia; thus, if
the adverse effects of an HO-1/ state involve these
cytokines, such effects would be ‘distal’ to cytokine gene
expression.
A notable finding was obtained with MMP-9, a basement
membrane-disrupting molecule of interest in access dysfunc-
tion. Although required in physiological processes, MMP-9,
when induced aberrantly or inordinately, can injure tissues,
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Figure 3 | mRNA expression of HO-1 and other genes in the vein in the AVF in HO-1þ /þ and HO-1/ mice, and
immunohistochemical localization of HO-1 protein in the AVF in HO-1þ /þ mice, undertaken 1 week after creation of the AVF.
mRNA expression for HO-1 (a), PAI-1 (b), MCP-1 (c), and PDGFa (d) was determined by quantitative real-time reverse transcriptase-
polymerase chain reaction. For each group n¼ 6–10. *Po0.05, HO-1/ mice versus HO-1þ /þ mice for the AVF. wPo0.05, HO-1/ mice
versus HO-1þ /þ mice for the control vein. The control was provided by the contralateral, intact, jugular vein. Immunohistochemical
localization of HO-1 protein in the AVF in HO-1þ /þ mice is shown in (e, f) (original magnification  400, AVFs from 2 HO-1þ /þ mice) and in
the contralateral, intact (control) jugular vein in HO-1þ /þ mice in (g) (original magnification  400). As shown in panels (e) and (f), strong
expression of HO-1 in the AVF was exhibited predominantly by cells with phenotypic characteristics of smooth-muscle cells, some of which
are labeled by closed arrows; expression of HO-1 was also exhibited by cells, considerably fewer in number in the AVF, and which had
phenotypic characteristics of leukocytes, some of which are labeled by open arrows. No such expression of HO-1 was observed in the
contralateral, intact (control) jugular vein in HO-1þ /þ mice (g), the latter showing staining for HO-1 only in some of the endothelial cells (g);
staining for HO-1 was also observed in some of the endothelial cells in the AVF (e, f). Immunohistochemical localization was performed
using a polyclonal antibody (SPA-895; Stressgen, Ann Arbor, MI, USA).
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and is incriminated in the pathogenesis of autoimmune
diseases, access dysfunction, and atherosclerosis.5,6,8,22–24 By
disrupting basement membranes, MMP-9 facilitates prolif-
eration and migration of smooth-muscle cells, and the influx
of inflammatory cells, processes fundamental to the patho-
genesis of neointimal hyperplasia and atherosclerosis, and
destabilization of atherosclerotic plaques; MMP-9 may
promote outward as well as inward remodeling.5,6,8,22–24 A
nuclear factor-kB-dependent gene, MMP-9 is inducible by
oxidants and proinflammatory cytokines, and in prior
studies, MMP-9 was induced by increased production of
peroxynitrite. We speculate that the exaggerated induction of
MMP-9 in HO-1/ mice adversely affects the AVF in this
mutant strain, and such induction reflects the prooxidant
effects, proinflammatory effects, or increased nuclear factor-
kB activation recognized in an HO-1 deficiency state.
That HO-1 deficiency adversely affects the function of an
AVF raises the possibility that overexpression of HO-1 or the
provision of its products may safeguard the functionality of
an AVF. Easily accessible because of its superficial position,
the AVF can be readily targeted by locally applied therapies,
the efficacy of such therapies founded on HO-1 and its
products would thus be of interest.
MATERIALS AND METHODS
All studies were approved by the IACUC of the Mayo Clinic and
performed in accordance with NIH guidelines. An AVF was
constructed, as previously described, by an end-to-side anastomosis
between the right common carotid artery and jugular vein in mice
weighing 25–35 g.14,22 The HO-1þ /þ and HO-1/ murine colony
was maintained as previously described, and mice were age-matched
(in the range of 18 to 53 weeks) and sex-matched in all studies.30,32
mRNA gene expression was assessed by quantitative real-time
reverse transcriptase-polymerase chain reaction in the AVF at 1
week, whereas at 3 weeks, histological and morphometric studies
were evaluated in perfusion-fixed AVFs.30,32,33 Gel zymography and
western analysis were performed on venous protein extract
fractionated by electrophoresis; immunoblotting was performed
with polyclonal anti-MMP-9 and anti-MMP-2 antibodies (R&D
Systems, Minneapolis, MN, USA) overnight at 4 1C.34,35
STATISTICS
Data are expressed as mean±s.e. Comparisons between HO-1/
and HO-1þ /þ mice for that condition were performed with the
Student’s t-test and the Mann-Whitney test for parametric and
nonparametric data respectively. Results are considered significant
for Po0.05.
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